© 2022 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#EASL 2018
Curing Hepatitis C Is Associated With a Reduced Risk of Death
Click Here for EASL.eu
An Introduction to Hepatitis
Anthony Tan, MD, at EASL 2018

Personalized Immunotherapy Shows Promise for Liver Cancer

Engineered T cells prevent recurrence over five years.

52nd International Liver Congress Roundup

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

Two Nations Make Progress in Eliminating Hepatitis C

Iceland and Georgia both have instigated aggressive testing and treatment initiatives.

Most Clinicians Conducting Hepatitis C Tests Are Poor at Linking to Care

Primary care physicians and ob-gyns are the top clinicians ordering such tests.

Few U.S. States Are on Track to Meet WHO Hep C Screening Targets

The World Health Organization wants to see 90 percent of the world’s population screened for hepatitis C by 2030.

Global Treatment of Hepatitis C Is Rising Quickly

But only a small fraction of those living with the virus worldwide have been cured.

MUST read

Hepatitis C: The Basics
Hepatitis B: The Basics
NASH: The Basics

Real-World Hepatitis C Cure Rates Are Excellent in Europeans With HIV

In a recent study of more than 600 HIV-positive adults, 93 percent were cured of hep C.
Jens Ricke speaks at EASL International Liver Congress

Local Therapies With Nexavar Do Not Improve Liver Cancer Survival

Adding internal radiation or TACE did appear to help certain people, however.

Experimental Hepatitis B Drug, JNJ-6369, Shows Promise in Early Trial

The drug has already advanced to a Phase IIa trial.

Early Trial of Experimental Hepatitis B Agent Sets Stage for Cure Research

Researchers examined the effects of an agent known as RO7049389 among people with and without hepatitis B.

Costs Spike for Treating NAFLD/NASH After a Cirrhosis Diagnosis

The costs rise particularly steeply for those who quickly progress to end-stage liver disease.

Hot topics

Forums: Support and discussion
Blogs: The community speaks

Treating Hep C Earlier Likely Saves Money, Improves Health Outlook

This is according to a recent mathematical modeling study.

New Hepatitis C Drugs Have Reduced the Need for Liver Transplants

A European liver transplant registry saw a decline in hep C as a cause of needing a transplant.

High Cure Rate for Hep C Combo That Could Go for $300 in Poorer Nations

Sovaldi (sofosbuvir) plus the new hep C drug ravidasvir cured 97 percent of those with a range of genotypes in a recent study.

Multidrug-Resistant Infections Common in Those With Cirrhosis

About one third of those in a global study of individuals hospitalized with cirrhosis had such infections.

Hepatitis B, C and Stigma Research From the 2018 International Liver Congress

More hepatitis research from the 2018 International Liver Congress.
Advertisement
Science News
Newsfeed
Features
Ask Hep